Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder

Lecanemab Phase III Readout Next Major Milestone

Executive Summary

In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention

Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.

Eisai/Biogen Maintain Lead Over Lilly In New Race To Alzheimer’s Approval

The US FDA accepted an application for accelerated approval and set a 6 January action date, giving lecanemab ample time to reach the market ahead of Lilly’s competing anti-amyloid antibody donanemab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel